Leveraging the Gut Microbiota for Mechanistically Informed Therapeutics against Body-First Parkinson's Disease.
- 1Department of Chemistry, University of California, Irvine, California 92617, United States.
- 2Department of Molecular Biology and Biochemistry, University of California, Irvine, California 92617, United States.
Abstract
Although some symptoms of Parkinson's disease can be pharmacologically alleviated, stopping disease progression is not currently possible. Motor impairment in Parkinson's disease is associated with accumulation of aggregates of the protein α-synuclein (α-syn) in dopaminergic neurons in the brain. In some Parkinson's disease cases, these pathogenic aggregates accumulate in the intestinal lining years before motor symptoms manifest. This long prodromal period provides a window of opportunity to detect Parkinson's disease and halt its progression. Specifically, elucidating the factors involved in disease onset in the gut would enable prevention of α-syn aggregation before it spreads to the brain. In this perspective, we highlight discoveries of gut bacteria that induce aggregation of intestinal α-syn as well as efforts to decipher the molecular-level mechanisms by which this process occurs. We also showcase the rationale and potential breadth of applications focused on manipulating the gut microbiome, including biotics, fecal microbiome transplants, and microbial editing. By understanding molecular mechanisms of intestinal α-syn aggregation, the microbiome may be harnessed to control the factors responsible for their pathogenic formation and spread. Such insights will ultimately enable the development of more effective therapeutics for prevention and treatment of Parkinson's disease.
Related
- From dosage alteration to amplification strategies: mechanistically defined alpha-synuclein mouse models for Parkinson's disease therapy development.
- Evaluating and leveraging large language models in clinical pharmacology and therapeutics assessment: From exam takers to exam shapers
- Advancing Therapeutics for Children with Medical Complexity: The Role of Model‐Informed Precision Dosing and Genotype‐Stratified Trials
- Microbiota-regulated TCDCA associates with Parkinson’s disease severity and promotes BBB dysfunction through VSMC TGR5 signaling in mice
- Clinical relevance of MRI-informed motor progression phenotypes in early Parkinson’s disease
BibTeX
@article{balsamo2026leveraging,
title = {{Leveraging the Gut Microbiota for Mechanistically Informed Therapeutics against Body-First Parkinson's Disease.}},
author = {Julia M Balsamo and Elizabeth N Bess},
journal = {ACS bio \& med chem Au},
year = {2026},
month = aug,
doi = {10.1021/acsbiomedchemau.6c00110},
url = {https://europepmc.org/article/MED/42921324},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Leveraging the Gut Microbiota for Mechanistically Informed Therapeutics against Body-First Parkinson's Disease.
AU - Julia M Balsamo
AU - Elizabeth N Bess
PY - 2026
DA - 2026/08/17
JO - ACS bio & med chem Au
DO - 10.1021/acsbiomedchemau.6c00110
UR - https://europepmc.org/article/MED/42921324
AB - Although some symptoms of Parkinson's disease can be pharmacologically alleviated, stopping disease progression is not currently possible. Motor impairment in Parkinson's disease is associated with accumulation of aggregates of the protein α-synuclein (α-syn) in dopaminergic neurons in the brain. In some Parkinson's disease cases, these pathogenic aggregates accumulate in the intestinal lining years before motor symptoms manifest. This long prodromal period provides a window of opportunity to detect Parkinson's disease and halt its progression. Specifically, elucidating the factors involved in disease onset in the gut would enable prevention of α-syn aggregation before it spreads to the brain. In this perspective, we highlight discoveries of gut bacteria that induce aggregation of intestinal α-syn as well as efforts to decipher the molecular-level mechanisms by which this process occurs. We also showcase the rationale and potential breadth of applications focused on manipulating the gut microbiome, including biotics, fecal microbiome transplants, and microbial editing. By understanding molecular mechanisms of intestinal α-syn aggregation, the microbiome may be harnessed to control the factors responsible for their pathogenic formation and spread. Such insights will ultimately enable the development of more effective therapeutics for prevention and treatment of Parkinson's disease.
SN - 2694-2437
ER -